Trials / Recruiting
RecruitingNCT03310905
Abdominal Wall Transplant
Abdominal Wall Transplantation for the Reconstruction of Abdominal Wall Defects as Adjunct to Abdominal Solid Organ Transplantation
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 5 (estimated)
- Sponsor
- Duke University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this protocol is to determine the safety and efficacy of abdominal wall transplantation as a treatment for the reconstruction of abdominal wall defects. Abdominal wall transplantation may be performed alone or in combination with another transplant.
Detailed description
Within this protocol we propose to perform abdominal wall transplantation in 5 subjects, either as an isolated abdominal wall or in combination with another organ transplant. Each subject will be followed for a study period of 18 months. Participants receiving an isolated abdominal wall or abdominal wall in combination with another organ transplant will receive the standard immunosuppression therapy as the non-vascularized composite allograft organ transplant. These patients will be studied to determine efficacy of the abdominal wall transplant to restore function of the defective abdominal wall for a study period of 18 months at Duke University Medical Center.
Conditions
- Transplant;Failure,Kidney
- Transplant; Failure, Liver
- Transplant; Failure, Bowel
- Abdominal Wall Defect
- Abdominal Wall Fistula
- Abdominal Wall Hernia
- Abdominal Wall Injury
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Abdominal Wall Transplant with another solid organ transplant | Transplant of abdominal wall in combination with another solid organ transplant. |
| PROCEDURE | Abdominal Wall Transplant alone | Abdominal Wall Transplant alone |
Timeline
- Start date
- 2018-05-01
- Primary completion
- 2028-01-01
- Completion
- 2028-06-01
- First posted
- 2017-10-16
- Last updated
- 2026-01-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03310905. Inclusion in this directory is not an endorsement.